Aparna Raychaudhuri Selected Research

lifitegrast

7/2019	Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease.
1/2018	Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial.
1/2017	Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
10/2016	Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials.
6/2016	Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study.
12/2015	Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Aparna Raychaudhuri Research Topics

Disease

6	Dry Eye Syndromes (Dry Eye Syndrome) 07/2019 - 12/2015
2	Pain (Aches) 07/2019 - 01/2017
2	Gonorrhea 12/2018 - 01/2018
2	Inflammation (Inflammations) 01/2017 - 12/2015
2	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 10/2013 - 07/2013
2	Multiple Sclerosis 09/2008 - 09/2006
1	Bacterial Infections (Bacterial Infection) 01/2022
1	Plague (Bubonic Plague) 01/2022
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2020
1	Urinary Tract Infections (Urinary Tract Infection) 01/2020
1	Dysgeusia (Parageusia) 07/2019
1	Fever (Fevers) 01/2019
1	Headache (Headaches) 01/2019
1	Pruritus (Itching) 01/2017
1	Photophobia (Light Sensitivity) 01/2017
1	Foreign Bodies (Foreign Body) 01/2017
1	Schizophrenia (Dementia Praecox) 12/2014
1	Infections 09/2008
1	Pathologic Complete Response 09/2008
1	Relapsing-Remitting Multiple Sclerosis 09/2008
1	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 09/2007
1	Breast Neoplasms (Breast Cancer) 09/2006

Drug/Important Bio-Agent (IBA)

6	lifitegrastIBA 07/2019 - 12/2015
4	gepotidacinIBA 01/2022 - 01/2018
3	Lisdexamfetamine Dimesylate FDA Link 12/2014 - 07/2013
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 01/2020
2	Pharmaceutical PreparationsIBA 01/2019 - 09/2008
2	InterleukinsIBA 09/2008 - 09/2006
2	Interleukin-12 (IL 12)IBA 09/2008 - 09/2006
2	Monoclonal AntibodiesIBA 09/2008 - 09/2006
1	Bacterial DNAIBA 01/2022
1	DNA Topoisomerase IV (Topoisomerase IV)IBA 01/2022
1	Nitrofurantoin (Macrodantin)FDA LinkGeneric 01/2020
1	Topoisomerase InhibitorsIBA 01/2018
1	Lymphocyte Function-Associated Antigen-1 (LFA-1)IBA 01/2017
1	IntegrinsIBA 12/2015
1	Dextroamphetamine (Dexedrine)FDA LinkGeneric 12/2014
1	ProdrugsIBA 12/2014
1	Antipsychotic Agents (Antipsychotics)IBA 12/2014
1	GadoliniumIBA 09/2008
1	Ustekinumab (CNTO 1275)FDA Link 09/2008
1	Infliximab (Remicade)FDA Link 09/2007
1	Methotrexate (Mexate)FDA LinkGeneric 09/2007

Therapy/Procedure

1	Renal Dialysis (Hemodialysis) 01/2020
1	Therapeutics 12/2018
1	Drug Therapy (Chemotherapy) 12/2014
1	Subcutaneous Injections 09/2008